{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:22:20Z","timestamp":1747196540560,"version":"3.40.5"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objective<\/jats:title>\n<jats:p>Assessing the histology-specific prognosis of epithelial ovarian cancer (OvCa) is clinically challenging, especially in a patient population with a favorable prognosis. This study investigated the histology-specific long-term oncologic outcomes in OvCa patients who underwent complete tumor resection using a large-scale patient cohort form multiple institutions under a central pathological review system.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>A regional multi-institutional study was conducted from 1986 to 2019. Of the 4,898 patients with ovarian tumors enrolled, 1,175 patients who underwent complete tumor resection were classified into three classes based on clinically important prognostic factors: stage, cytology, ascites volume. For each class category, the effect of histology types on recurrence-free survival, the site of recurrence, and post-recurrence survival was evaluated.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Recurrence-free survival varied significantly across different histologies (P &lt; 0.001). The risk of recurrence was higher in serous carcinoma compare to other histologies (P &lt; 0.001). The site of tumor recurrence varied by the histology type. Multinominal logistic regression analysis revealed that mucinous histology had a significantly higher likelihood of developing recurrent tumors at distant sites from the peritoneum compared to other histologies (P = 0.002). Conversely, serous histology was associated with better post-recurrence survival (Log-rank P &lt; 0.001).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Long-term oncologic outcomes significantly differ by histology type in OvCa patients who have undergone complete tumor resection at the initial surgery. A careful evaluation of the clinical background is necessary for these patients, and further clinical research into individualized treatment approaches is essential.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0311421","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T18:33:57Z","timestamp":1732559637000},"page":"e0311421","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Histology-specific long-term oncologic outcomes in patients with epithelial ovarian cancer who underwent complete tumor resection: The implication of occult seeds after initial surgery"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3866-2566","authenticated-orcid":true,"given":"Kazumasa","family":"Mogi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5811-3137","authenticated-orcid":true,"given":"Masato","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Emoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiri","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaname","family":"Uno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Tano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Iyoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhisa","family":"Kitami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8662-9421","authenticated-orcid":true,"given":"Nobuhisa","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeyuki","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Kajiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"issue":"3","key":"pone.0311421.ref001","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.","volume":"71","author":"H Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"pone.0311421.ref002","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3322\/caac.21456","article-title":"Ovarian cancer statistics, 2018.","volume":"68","author":"LA Torre","year":"2018","journal-title":"CA Cancer J Clin."},{"issue":"5","key":"pone.0311421.ref003","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.","volume":"20","author":"RE Bristow","year":"2002","journal-title":"J Clin Oncol"},{"issue":"6","key":"pone.0311421.ref004","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","article-title":"Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d\u2019Investigateurs Nationaux Pour les Etudes des Cancers de l\u2019Ovaire (GINECO).","volume":"115","author":"A du Bois","year":"2009","journal-title":"Cancer"},{"key":"pone.0311421.ref005","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejogrb.2021.11.015","article-title":"Long-term post-recurrence survival outcomes in young women receiving fertility-sparing surgery for epithelial ovarian cancer","volume":"267","author":"M Shigeyama","year":"2021","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"5","key":"pone.0311421.ref006","doi-asserted-by":"crossref","first-page":"6298","DOI":"10.18632\/oncotarget.23921","article-title":"The possible existence of occult metastasis in patients with ovarian clear-cell carcinoma who underwent complete resection without any residual tumours.","volume":"9","author":"H Kajiyama","year":"2018","journal-title":"Oncotarget"},{"issue":"10 Suppl","key":"pone.0311421.ref007","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1002\/cncr.11345","article-title":"Pathology and classification of ovarian tumors","volume":"97","author":"VW Chen","year":"2003","journal-title":"Cancer"},{"issue":"1","key":"pone.0311421.ref008","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ajpath.2020.09.006","article-title":"The Origin of Ovarian Cancer Species and Precancerous Landscape","volume":"191","author":"IM Shih","year":"2021","journal-title":"Am J Pathol"},{"issue":"2","key":"pone.0311421.ref009","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.3802\/jgo.2021.32.e49","article-title":"The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.","volume":"32","author":"H Tokunaga","year":"2021","journal-title":"J Gynecol Oncol."},{"issue":"3","key":"pone.0311421.ref010","first-page":"541","article-title":"Board Members of the 2020 Committee on Gynecologic Oncology of the Japan Society of Obstetrics and Gynecology. Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual Patient Report for 2018 and Annual Treatment Report for 2013","volume":"48","author":"S Nagase","year":"2022","journal-title":"J Obstet Gynaecol Res"},{"issue":"2","key":"pone.0311421.ref011","doi-asserted-by":"crossref","first-page":"191","DOI":"10.6004\/jnccn.2021.0007","article-title":"Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.","volume":"19","author":"DK Armstrong","year":"2021","journal-title":"J Natl Compr Canc Netw."},{"issue":"5","key":"pone.0311421.ref012","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00404-014-3364-8","article-title":"The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer","volume":"290","author":"F Zeppernick","year":"2014","journal-title":"Arch Gynecol Obstet"},{"issue":"4","key":"pone.0311421.ref013","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.3802\/jgo.2022.33.e40","article-title":"Survival benefits of retroperitoneal lymphadenectomy for optimally-resected advanced ovarian high-grade serous carcinoma: a multi-institutional retrospective study.","volume":"33","author":"Y Ikeda","year":"2022","journal-title":"J Gynecol Oncol"},{"issue":"2","key":"pone.0311421.ref014","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).","volume":"21","author":"GJ Rustin","year":"2011","journal-title":"Int J Gynecol Cancer."},{"issue":"1","key":"pone.0311421.ref015","doi-asserted-by":"crossref","first-page":"15154","DOI":"10.1038\/s41598-021-93718-3","article-title":"A large-scale multi-institutional study evaluating prognostic aspects of positive ascites cytology and effects of therapeutic interventions in epithelial ovarian cancer","volume":"11","author":"M Yoshihara","year":"2021","journal-title":"Sci Rep"},{"issue":"3","key":"pone.0311421.ref016","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ygyno.2017.06.008","article-title":"Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study","volume":"146","author":"JB Szender","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"12","key":"pone.0311421.ref017","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1136\/ijgc-2021-002978","article-title":"Ascites volume at the time of primary debulking and overall survival of patients with advanced epithelial ovarian cancer","volume":"31","author":"D Nasioudis","year":"2021","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"pone.0311421.ref018","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1006\/gyno.2001.6536","article-title":"Survival among U.S. women with invasive epithelial ovarian cancer","volume":"84","author":"V McGuire","year":"2002","journal-title":"Gynecol Oncol"},{"issue":"2","key":"pone.0311421.ref019","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ygyno.2016.11.019","article-title":"Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2).","volume":"144","author":"M Matz","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"11","key":"pone.0311421.ref020","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1002\/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5","article-title":"Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy","volume":"88","author":"T Sugiyama","year":"2000","journal-title":"Cancer"},{"issue":"6","key":"pone.0311421.ref021","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.2004.08.078","article-title":"Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment.","volume":"22","author":"V Hess","year":"2004","journal-title":"J Clin Oncol"},{"issue":"3","key":"pone.0311421.ref022","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","article-title":"Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin","volume":"9","author":"M Markman","year":"1991","journal-title":"J Clin Oncol"},{"issue":"3","key":"pone.0311421.ref023","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ygyno.2013.05.040","article-title":"Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis","volume":"130","author":"SJ Chang","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"1","key":"pone.0311421.ref024","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ygyno.2017.01.029","article-title":"Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible","volume":"145","author":"S Wallace","year":"2017","journal-title":"Gynecol Oncol"},{"key":"pone.0311421.ref025","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12957-016-0800-1","article-title":"Results of optimal debulking surgery with bowel resection in patients with advanced ovarian cancer","volume":"14","author":"P Derlatka","year":"2016","journal-title":"World J Surg Oncol"},{"key":"pone.0311421.ref026","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1757-2215-7-72","article-title":"Prognostic role of bowel involvement in optimally cytoreduced advanced ovarian cancer: A retrospective study.","volume":"7","author":"G Giorda","year":"2014","journal-title":"J Ovarian Res"},{"issue":"1","key":"pone.0311421.ref027","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1245\/s10434-020-08989-3","article-title":"Hepatobiliary Disease Resection in Patients with Advanced Epithelial Ovarian Cancer: Prognostic Role and Optimal Cytoreduction","volume":"28","author":"V Di Donato","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"pone.0311421.ref028","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11912-020-0883-2","article-title":"Lymphadenectomy in Ovarian Cancer: Is It Still Justified","volume":"22","author":"P Benedetti Panici","year":"2020","journal-title":"Curr Oncol Rep"},{"issue":"9","key":"pone.0311421.ref029","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1056\/NEJMoa1808424","article-title":"A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms","volume":"380","author":"P Harter","year":"2019","journal-title":"N Engl J Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0311421","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T18:34:15Z","timestamp":1732559655000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0311421"}},"subtitle":[],"editor":[{"given":"Alison May","family":"Berner","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0311421","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2024,11,25]]}}}